Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 1,381-1,392 of 4,306
Drug study icon
CompletedNCT00057707

Effects of Modafinil on Brain Function in people with Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Bethesda
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.From 18 Years to 50 Years
Countries
United States
Sponsor
National Institute of Mental Health (NIMH)
Condition
Schizophrenia
Drug study icon
CompletedNCT00231335

Escitalopram Augmentation for schizophrenia

This study is completed. It is testing escitalopram Augmentation for schizophrenia.

Location not clearly listed
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 55 Years
Countries
Sponsor
Emory University
Condition
Schizophrenia
Other study type icon
CompletedNCT00615511

Efficacy of Pregnenolone in people with Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Piscataway
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Weill Medical College of Cornell University
Condition
Schizophrenia
Drug study icon
CompletedNCT00337662

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, Argentina, Russia
Sponsor
Eli Lilly and Company
Condition
Schizophrenia
Drug study icon
CompletedNCT00176423

Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Baltimore
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
Drug study icon
CompletedNCT00401089

Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Kingston
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
Canada, United Kingdom
Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Condition
Schizophrenia
Behavioral study icon
CompletedNCT05712928

eMove - Dance/Movement Therapy Study

This summary needs review. Please check the official study record and contact the research team for details.

In Philadelphia
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaBehavioralOver 18 Years
Countries
United States
Sponsor
Drexel University
Condition
Schizophrenia
Other study type icon
CompletedNCT01092598

Factors Association With Poor Physical Function in Older Adults With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In San Francisco
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaObservationalA study where researchers collect information without assigning a treatment.Over 55 Years
Countries
United States
Sponsor
University of California, San Francisco
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.